One example is the GLP-1 homologue peptide exendin-4 (Eng et al., 1992), in clinical use for T2D as exenatide
Abdominal constrictions and wet dog shakes were scored as graded symptoms, while facial fasciculations, ptosis, abnormal posture, and genital grooming were scored as all-or-nothing symptoms
That is nearly a year of continuous treatment, and the results paint a clear picture of what happens when people stay on this compound without interruption
Optimizing results while on GLP-1 therapy Peptides alone won't maximize outcomes
Notably, clinical observations indicate that endocrine therapy resistance is closely associated with oestrogen-dependent redox signal dysregulation mediated by ROS, suggesting that targeting ROS homeostasis may represent a novel breakthrough for reversing drug resistance [127]